Media Articles Related to Prolixin (Fluphenazine)
Perspective-taking difficulties diminished when autistic and psychosis tendencies balance
Source: Autism News From Medical News Today [2015.05.15]
Researchers at the University of Birmingham have shed new light on the relationship between autistic tendencies and psychosis proneness in neurotypical adults.
Source: MedicineNet Biorhythms Specialty [2015.05.14]
Title: ICU Psychosis
Category: Diseases and Conditions
Created: 12/10/1998 12:00:00 AM
Last Editorial Review: 5/14/2015 12:00:00 AM
Findings presented at the Society for Neuroscience meeting by Johns Hopkins scientists
Source: Huntingtons Disease News From Medical News Today [2014.11.24]
A Blood Pressure Hormone Implicated in PsychosisIn an effort to find a marker that predicts psychosis, postdoctoral researcher Lindsay Hayes, Ph.D.
Published Studies Related to Prolixin (Fluphenazine)
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. [2007.03.30]
Pharmacotherapy of schizophrenia is associated with the stressful side effects...
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. [2006.04]
Sexual dysfunction is common in people suffering from schizophrenia and is reported by patients to be a significant reason for medication nonadherence. This report contains data for 27 people with schizophrenia who participated in a randomized double-blind 12-week trial of risperidone (4 mg/day), quetiapine (400 mg/day) or fluphenazine (12.5 mg/day)...
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. [2005.07]
This 12-week, double-blind study evaluated the effectiveness of risperidone (4 mg/day), quetiapine (400 mg/day), or fluphenazine (12.5 mg/day) in a stringently defined treatment-resistant population of people with schizophrenia. No differences were noted in total Brief Psychiatric Rating Scale (BPRS) or Clinical Global Impression scores among the drug groups (n = 38)...
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. [2005.01]
CONCLUSIONS: It is expected that TT(4) levels will decrease during quetiapine treatment, and this may possibly be related to competitive metabolism of thyroid hormones and quetiapine by UDP-glucuronosyltransferase. Routine monitoring of thyroid function in quetiapine-treated patients without a history of thyroid disease is not recommended.
Fluphenazine (oral) versus placebo for schizophrenia. 
CONCLUSIONS: The findings in this review confirm much that clinicians
Clinical Trials Related to Prolixin (Fluphenazine)
Fluphenazine Hydrochloride for Psoriasis [Recruiting]
The objective of this study is to assess the safety and biologic activity of intralesional
injection of fluphenazine in adult subjects with psoriasis.
Fluphenazine Decanoate for Psoriasis [Terminated]
We are doing this research study to evaluate the effectiveness and safety of fluphenazine
decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine
decanoate is FDA (U. S. Food and Drug Administration) approved for use in people who have
schizophrenia and psychotic symptoms. Fluphenazine decanoate is not approved by the FDA for
use in psoriasis. Fluphenazine decanoate slows T cell growth in cells in laboratory test
tubes. Its usefulness and safety in people with psoriasis will be investigated in this
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma [Completed]
RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine and
to see how well it works in treating patients with refractory advanced multiple myeloma.
New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia [Active, not recruiting]
The purpose of this study is to:
1. Evaluate the efficacy and safety of the new antipsychotics, quetiapine (300-500mg/day)
and risperidone (3-4mg/day) compared to each other and to fluphenazine (10-15mg/day), a
high potency typical antipsychotic in patients who meet the DSM IV criteria for
2. To evaluate the efficacy and safety of quetiapine (1200mg/day) in patients who have not
responded to conventional and newer antipsychotics.
3. To evaluate the effectiveness of quetiapine (300-500mg/day), and risperidone (3-5mg/day)
compared to each other and fluphenazine (10-15mg/day) in the treatment of hostility and
aggression in treatment-resistant schizophrenic patients.
4. To evaluate the effectiveness of quetiapine (300-500mg/day) and risperidone (3-5mg/day)
compared to each other and fluphenazine (10-15mg/day) on rates of discharge, quality of
life, and independent living skills.
5. To assess prolactin levels and to evaluate any relationship with sexual dysfunction and
6. To evaluate the possible differential impact of treatment conditions on cognitive
functioning including measures of attention, motor speed, problem solving, verbal and
visual memory, and verbal processing speed.
7. To measure changes in weight and health consequences associated with weight changes.
A Comparison of Long-acting Injectable Medications for Schizophrenia [Recruiting]
The purpose of this research study is to compare the "real-world" effectiveness of two
FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone
palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective
disorder who are expected to benefit from the improved medication compliance associated with
injectable medications. The goal is to evaluate the effects of the medications on outcomes
of importance to patients (relapse, symptoms, adverse effects, functioning) as well as
policy makers (all of the above plus costs).
Reports of Suspected Prolixin (Fluphenazine) Side Effects
Neuroleptic Malignant Syndrome (3),
Drug Interaction (2),
Cardiac Disorder (2),
Brain Injury (2),
Weight Increased (2),
Myocardial Infarction (2),
Tardive Dyskinesia (2), more >>